clomipramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
substances of the imipramine group 701 303-49-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clomipramine
  • chlorimipramine
  • clomipramine hydrochloride
  • clomipramine HCl
A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
  • Molecular weight: 314.86
  • Formula: C19H23ClN2
  • CLOGP: 5.92
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.34
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.24 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 51 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 13 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 26 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 57
kinase-selectivity-class EIF2AK3,PDK4,STK33,TTK 4
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.530 Moderate 0.76
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
rat-kpuu-brain Rat brain Kpuu 0.685 % Moderate 0.76

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1989 FDA MALLINCKRODT LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicide attempt 328.96 18.16 176 12658 75223 90540390
Coma 306.92 18.16 166 12668 72466 90543147
Intentional overdose 264.84 18.16 165 12669 93669 90521944
Poisoning deliberate 226.77 18.16 86 12748 16400 90599213
Suicidal ideation 226.52 18.16 137 12697 73718 90541895
Serotonin syndrome 225.03 18.16 109 12725 37778 90577835
Drug interaction 198.47 18.16 219 12615 276234 90339379
Overdose 141.70 18.16 141 12693 157568 90458045
Depressed level of consciousness 126.59 18.16 95 12739 72689 90542924
Intentional self-injury 126.40 18.16 68 12766 29266 90586347
Toxicity to various agents 121.45 18.16 175 12659 287671 90327942
Bezoar 105.29 18.16 31 12803 2703 90612910
Sopor 100.25 18.16 55 12779 24589 90591024
Altered state of consciousness 95.30 18.16 58 12776 31474 90584139
Neuroleptic malignant syndrome 94.32 18.16 45 12789 15051 90600562
Tremor 93.87 18.16 112 12722 153061 90462552
Antipsychotic drug level increased 91.36 18.16 30 12804 3749 90611864
Drug abuse 89.79 18.16 82 12752 82265 90533348
Electrocardiogram QT prolonged 86.61 18.16 76 12758 72380 90543233
Tachycardia 83.28 18.16 107 12727 157566 90458047
Somnolence 79.27 18.16 121 12713 208963 90406650
Agitation 75.46 18.16 68 12766 67030 90548583
International normalised ratio abnormal 71.24 18.16 25 12809 3820 90611793
Pain 66.71 18.16 29 12805 996312 89619301
Antidepressant drug level increased 63.27 18.16 14 12820 384 90615229
Akathisia 62.88 18.16 31 12803 11128 90604485
Hyperthermia 59.10 18.16 29 12805 10306 90605307
Psychomotor hyperactivity 58.83 18.16 31 12803 12782 90602831
Hypotension 58.68 18.16 137 12697 325260 90290353
Disturbance in attention 57.46 18.16 50 12784 47059 90568554
Joint swelling 55.93 18.16 4 12830 503296 90112317
Cerebellar syndrome 52.50 18.16 20 12814 3852 90611761
Myoclonus 52.18 18.16 33 12801 19135 90596478
Sinus tachycardia 49.04 18.16 37 12797 28476 90587137
Polyuria 48.12 18.16 25 12809 10015 90605598
Hyposmia 46.31 18.16 13 12821 956 90614657
Poisoning 45.99 18.16 28 12806 15189 90600424
Mental disorder 44.95 18.16 37 12797 32281 90583332
Inappropriate antidiuretic hormone secretion 44.35 18.16 30 12804 19475 90596138
Hypertonia 43.67 18.16 19 12815 5136 90610477
Pneumonia aspiration 43.10 18.16 40 12794 40900 90574713
Parkinsonism 42.81 18.16 26 12808 14039 90601574
Mania 42.71 18.16 26 12808 14098 90601515
Arthralgia 41.45 18.16 30 12804 778492 89837121
Alopecia 40.77 18.16 10 12824 495061 90120552
Respiratory depression 40.37 18.16 26 12808 15549 90600064
Livedo reticularis 40.28 18.16 16 12818 3443 90612170
Hepatocellular injury 39.95 18.16 33 12801 28925 90586688
Muscle rigidity 39.86 18.16 25 12809 14284 90601329
Ventricular dyskinesia 38.96 18.16 8 12826 152 90615461
Hyperchloraemia 38.32 18.16 11 12823 877 90614736
Circulatory collapse 37.78 18.16 30 12804 24874 90590739
Shock 36.00 18.16 31 12803 28747 90586866
Restlessness 35.87 18.16 34 12800 35686 90579927
Dialysis 34.63 18.16 21 12813 11308 90604305
Hypotonia 34.46 18.16 21 12813 11405 90604208
Otorrhoea 34.00 18.16 12 12822 1863 90613750
Nasopharyngitis 33.95 18.16 8 12826 407096 90208517
Psychiatric decompensation 33.59 18.16 12 12822 1931 90613682
Swelling 33.47 18.16 9 12825 419049 90196564
Hyperprolactinaemia 33.34 18.16 16 12818 5417 90610196
Psychomotor skills impaired 32.45 18.16 13 12821 2859 90612754
Urinary retention 32.45 18.16 33 12801 37711 90577902
Fatigue 31.92 18.16 73 12761 1153950 89461663
Drug hypersensitivity 31.71 18.16 13 12821 463596 90152017
Contraindicated product administered 31.69 18.16 4 12830 320135 90295478
Cholestasis 31.68 18.16 32 12802 36267 90579346
Drug withdrawal syndrome neonatal 31.52 18.16 12 12822 2307 90613306
Intestinal obstruction 31.08 18.16 32 12802 37099 90578514
Lactic acidosis 31.02 18.16 37 12797 50426 90565187
Junctional ectopic tachycardia 30.90 18.16 7 12827 214 90615399
Cor pulmonale acute 30.78 18.16 8 12826 439 90615174
Rash 30.47 18.16 41 12793 796059 89819554
Obsessive-compulsive disorder 29.89 18.16 14 12820 4490 90611123
Glomerular filtration rate abnormal 29.80 18.16 10 12824 1335 90614278
Loss of consciousness 29.66 18.16 63 12771 140175 90475438
Blood prolactin increased 29.49 18.16 13 12821 3624 90611989
Post-anoxic myoclonus 29.45 18.16 5 12829 31 90615582
Hyponatraemia 29.42 18.16 61 12773 133477 90482136
Heat stroke 29.41 18.16 9 12825 895 90614718
Drug reaction with eosinophilia and systemic symptoms 29.04 18.16 33 12801 42725 90572888
Arthropathy 28.99 18.16 8 12826 366234 90249379
Newborn persistent pulmonary hypertension 28.82 18.16 7 12827 291 90615322
Therapeutic product effect decreased 28.64 18.16 3 12831 277568 90338045
Diarrhoea 27.93 18.16 57 12777 939133 89676480
Miosis 27.50 18.16 17 12817 9467 90606146
Cardio-respiratory arrest 27.42 18.16 39 12795 63101 90552512
Treatment failure 27.33 18.16 5 12829 303923 90311690
Vertigo 27.24 18.16 41 12793 69770 90545843
Status epilepticus 27.06 18.16 22 12812 18852 90596761
Retroplacental haematoma 26.76 18.16 6 12828 175 90615438
Rheumatoid arthritis 26.75 18.16 9 12825 362605 90253008
Foramen magnum stenosis 26.50 18.16 6 12828 183 90615430
Drug ineffective 26.32 18.16 305 12529 1383993 89231620
Dermo-hypodermitis 26.11 18.16 8 12826 799 90614814
Psychomotor retardation 26.08 18.16 13 12821 4776 90610837
Stereotypy 25.87 18.16 7 12827 449 90615164
Hallucination, auditory 25.86 18.16 20 12814 15955 90599658
Stomatitis 25.85 18.16 4 12830 274694 90340919
Product dose omission issue 25.80 18.16 5 12829 291682 90323931
Self-destructive behaviour 25.36 18.16 7 12827 484 90615129
Drug level increased 25.20 18.16 25 12809 27737 90587876
Apathy 25.14 18.16 17 12817 11023 90604590
Mobility decreased 25.14 18.16 3 12831 250731 90364882
Onychophagia 25.10 18.16 5 12829 81 90615532
Drug screen false positive 24.88 18.16 8 12826 935 90614678
Mydriasis 24.75 18.16 19 12815 14993 90600620
Hepatic cytolysis 24.72 18.16 26 12808 30890 90584723
Synovitis 24.64 18.16 8 12826 329744 90285869
Peripheral swelling 24.56 18.16 14 12820 413092 90202521
Spasmodic dysphonia 24.55 18.16 5 12829 91 90615522
Psychiatric symptom 23.85 18.16 14 12820 7104 90608509
Completed suicide 23.85 18.16 59 12775 144999 90470614
Otitis media 23.58 18.16 13 12821 5857 90609756
Hypersensitivity 23.53 18.16 18 12816 454659 90160954
Extrapyramidal disorder 23.37 18.16 19 12815 16284 90599329
Hypokalaemia 23.35 18.16 55 12779 131061 90484552
Adverse drug reaction 23.04 18.16 51 12783 116650 90498963
Nail avulsion 22.80 18.16 6 12828 346 90615267
Paralogism 22.67 18.16 4 12830 32 90615581
Illusion 22.58 18.16 8 12826 1256 90614357
Osteoporosis postmenopausal 22.45 18.16 6 12828 367 90615246
Cyanosis 22.41 18.16 20 12814 19435 90596178
Torsade de pointes 22.41 18.16 18 12816 15164 90600449
Iliotibial band syndrome 22.34 18.16 6 12828 374 90615239
Vertebral lesion 22.23 18.16 7 12827 765 90614848
Infection 21.91 18.16 12 12822 362082 90253531
Headache 21.89 18.16 57 12777 862689 89752924
Gastroduodenal ulcer 21.86 18.16 6 12828 406 90615207
Hepatic enzyme increased 21.76 18.16 12 12822 360724 90254889
Stupor 21.64 18.16 12 12822 5470 90610143
Gastrointestinal disorder 21.47 18.16 5 12829 256682 90358931
Asphyxia 21.28 18.16 13 12821 7090 90608523
Cervical vertebral fracture 21.12 18.16 10 12824 3283 90612330
Nasal turbinate hypertrophy 21.01 18.16 7 12827 914 90614699
Urticaria 20.99 18.16 9 12825 312725 90302888
Peripheral nerve lesion 20.99 18.16 6 12828 471 90615142
Abdominal discomfort 20.98 18.16 22 12812 477306 90138307
Somatic symptom disorder 20.71 18.16 10 12824 3431 90612182
Foetal arrhythmia 20.49 18.16 5 12829 212 90615401
Agranulocytosis 20.43 18.16 25 12809 34977 90580636
Hypernatraemia 20.30 18.16 14 12820 9373 90606240
Right ventricular dilatation 20.28 18.16 8 12826 1691 90613922
Acquired haemophilia 19.99 18.16 7 12827 1062 90614551
Haemolytic anaemia 19.71 18.16 15 12819 11682 90603931
Radial nerve palsy 19.52 18.16 6 12828 605 90615008
Hallucination, visual 19.50 18.16 20 12814 23072 90592541
Blister 19.38 18.16 6 12828 254992 90360621
Postnatal growth restriction 19.28 18.16 4 12830 80 90615533
Paranasal sinus inflammation 19.26 18.16 6 12828 633 90614980
Contusion 18.93 18.16 6 12828 251210 90364403
Conjunctivitis 18.79 18.16 21 12813 26685 90588928
Sinobronchitis 18.71 18.16 6 12828 695 90614918
Abulia 18.64 18.16 6 12828 703 90614910
Tardive dyskinesia 18.39 18.16 14 12820 10916 90604697
Nausea 18.35 18.16 88 12746 1110228 89505385
Dysplasia 18.18 18.16 7 12827 1387 90614226

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Obsessive-compulsive disorder 484.58 23.65 139 9939 6604 42604653
Antipsychotic drug level below therapeutic 469.04 23.65 116 9962 3088 42608169
Therapeutic product effect variable 457.33 23.65 113 9965 2996 42608261
Disinhibition 451.40 23.65 117 9961 3778 42607479
Suicide attempt 445.09 23.65 217 9861 45883 42565374
Euphoric mood 414.79 23.65 122 9956 6331 42604926
Akathisia 392.43 23.65 131 9947 10320 42600937
Increased appetite 359.84 23.65 118 9960 8788 42602469
Leukaemia 199.36 23.65 68 10010 5704 42605553
Toxicity to various agents 194.62 23.65 254 9824 228882 42382375
Therapeutic product effect incomplete 153.62 23.65 130 9948 70809 42540448
Dyslipidaemia 153.35 23.65 64 10014 9354 42601903
Neuroleptic malignant syndrome 140.44 23.65 78 10000 21394 42589863
Prescribed overdose 140.03 23.65 66 10012 12861 42598396
Weight increased 138.35 23.65 148 9930 107835 42503422
Serotonin syndrome 132.14 23.65 80 9998 25765 42585492
Intentional overdose 131.74 23.65 104 9974 51352 42559905
Obesity 127.76 23.65 67 10011 16392 42594865
Leukopenia 126.12 23.65 119 9959 74627 42536630
Coma 105.42 23.65 93 9985 53461 42557796
Poisoning deliberate 104.42 23.65 50 10028 10084 42601173
Intentional self-injury 104.26 23.65 57 10021 15145 42596112
Schizoaffective disorder 103.87 23.65 32 10046 1938 42609319
Extrapyramidal disorder 94.83 23.65 55 10023 16357 42594900
Irritability 85.46 23.65 63 10015 28065 42583192
Electrocardiogram QT prolonged 80.15 23.65 76 10002 47869 42563388
Megacolon 67.62 23.65 24 10054 2261 42608996
Sopor 62.67 23.65 39 10039 13163 42598094
Parkinsonism 62.42 23.65 36 10042 10587 42600670
Drug ineffective 55.17 23.65 293 9785 629904 41981353
Drug interaction 47.77 23.65 155 9923 266844 42344413
Loose associations 47.71 23.65 9 10069 61 42611196
Cogwheel rigidity 46.12 23.65 17 10061 1784 42609473
Tremor 44.35 23.65 81 9997 96848 42514409
Somnolence 43.35 23.65 100 9978 141005 42470252
Suicidal ideation 43.10 23.65 55 10023 48106 42563151
Agitation 41.87 23.65 63 10015 64251 42547006
Bradykinesia 41.79 23.65 22 10056 5414 42605843
Fatigue 41.51 23.65 26 10052 435615 42175642
Inappropriate antidiuretic hormone secretion 41.33 23.65 33 10045 16508 42594749
Mania 39.84 23.65 27 10051 10520 42600737
Compartment syndrome 39.35 23.65 18 10060 3271 42607986
Resting tremor 39.32 23.65 13 10065 988 42610269
Rhabdomyolysis 37.98 23.65 67 10011 77952 42533305
Renal hypertension 35.54 23.65 9 10069 263 42610994
Pneumonia 35.22 23.65 29 10049 422120 42189137
Dermatitis bullous 35.20 23.65 23 10055 8433 42602824
Patient elopement 34.44 23.65 8 10070 161 42611096
Brachial plexus injury 34.16 23.65 7 10071 76 42611181
Feelings of worthlessness 33.98 23.65 9 10069 315 42610942
Obsessive-compulsive symptom 31.92 23.65 8 10070 224 42611033
Arthralgia 30.08 23.65 6 10072 205232 42406025
Overdose 29.48 23.65 72 10006 105192 42506065
Confusional state 28.73 23.65 96 9982 167501 42443756
Diarrhoea 27.15 23.65 42 10036 460807 42150450
Hyperthermia 27.05 23.65 23 10055 12551 42598706
Aggression 26.95 23.65 42 10036 44121 42567136
Cough 26.53 23.65 5 10073 178098 42433159
Rash 25.68 23.65 17 10061 276937 42334320
Pain 25.58 23.65 13 10065 244835 42366422
Sepsis 25.02 23.65 8 10070 199326 42411931
Pressure of speech 24.82 23.65 8 10070 561 42610696
Adrenergic syndrome 24.63 23.65 6 10072 149 42611108
Dyspnoea 24.51 23.65 42 10036 442579 42168678
Hepatocellular injury 24.32 23.65 29 10049 23649 42587608
Hypertonia neonatal 24.27 23.65 8 10070 602 42610655
Poisoning 23.96 23.65 23 10055 14676 42596581

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicide attempt 568.89 18.32 300 18631 103094 110467274
Coma 408.41 18.32 253 18678 117616 110452752
Serotonin syndrome 351.79 18.32 181 18750 58972 110511396
Intentional overdose 345.38 18.32 238 18693 132263 110438105
Poisoning deliberate 315.33 18.32 131 18800 26200 110544168
Suicidal ideation 266.72 18.32 178 18753 93759 110476609
Neuroleptic malignant syndrome 252.14 18.32 121 18810 33938 110536430
Drug interaction 234.56 18.32 353 18578 499830 110070538
Obsessive-compulsive disorder 221.83 18.32 72 18859 7169 110563199
Toxicity to various agents 212.33 18.32 330 18601 480225 110090143
Akathisia 204.37 18.32 85 18846 17028 110553340
Intentional self-injury 173.20 18.32 97 18834 37332 110533036
Antipsychotic drug level below therapeutic 166.31 18.32 42 18889 1693 110568675
Sopor 161.77 18.32 92 18839 36454 110533914
Therapeutic product effect variable 152.15 18.32 43 18888 2675 110567693
Electrocardiogram QT prolonged 151.22 18.32 135 18796 108825 110461543
Overdose 149.71 18.32 192 18739 233602 110336766
Disinhibition 146.09 18.32 43 18888 3091 110567277
Extrapyramidal disorder 125.95 18.32 72 18859 28795 110541573
Euphoric mood 119.57 18.32 48 18883 8779 110561589
Bezoar 118.86 18.32 39 18892 4015 110566353
Tremor 118.43 18.32 159 18772 202073 110368295
Somnolence 115.62 18.32 193 18738 297256 110273112
Schizoaffective disorder 107.61 18.32 34 18897 3102 110567266
Parkinsonism 106.72 18.32 59 18872 22128 110548240
Depressed level of consciousness 103.09 18.32 111 18820 112167 110458201
Altered state of consciousness 101.66 18.32 82 18849 57544 110512824
Agitation 95.53 18.32 107 18824 112944 110457424
Irritability 90.68 18.32 71 18860 47738 110522630
Hyperthermia 89.97 18.32 52 18879 21220 110549148
Mania 88.39 18.32 51 18880 20745 110549623
Drug abuse 86.76 18.32 128 18803 177283 110393085
Increased appetite 83.69 18.32 44 18887 14933 110555435
Drug ineffective 79.76 18.32 487 18444 1520053 109050315
Pain 79.74 18.32 32 18899 954923 109615445
Dyslipidaemia 78.28 18.32 43 18888 15922 110554446
Inappropriate antidiuretic hormone secretion 76.89 18.32 56 18875 33795 110536573
Psychomotor hyperactivity 73.82 18.32 45 18886 20232 110550136
Tachycardia 68.65 18.32 132 18799 226513 110343855
Hepatocellular injury 66.76 18.32 61 18870 50581 110519787
Poisoning 65.77 18.32 48 18883 29057 110541311
Arthralgia 65.24 18.32 26 18905 779606 109790762
Antipsychotic drug level increased 64.57 18.32 29 18902 6986 110563382
Antidepressant drug level increased 64.47 18.32 16 18915 600 110569768
Rhabdomyolysis 60.47 18.32 88 18843 120313 110450055
Megacolon 60.35 18.32 24 18907 4281 110566087
Joint swelling 60.18 18.32 4 18927 442841 110127527
Muscle rigidity 57.42 18.32 41 18890 23990 110546378
Fatigue 57.07 18.32 75 18856 1215883 109354485
Bradykinesia 55.50 18.32 30 18901 10758 110559610
International normalised ratio abnormal 54.46 18.32 25 18906 6332 110564036
Infusion related reaction 53.11 18.32 3 18928 381159 110189209
Shock 52.74 18.32 55 18876 53533 110516835
Nasopharyngitis 52.31 18.32 4 18927 394357 110176011
Leukaemia 50.47 18.32 25 18906 7493 110562875
Myoclonus 49.97 18.32 43 18888 32955 110537413
Psychomotor retardation 49.62 18.32 25 18906 7767 110562601
Disturbance in attention 49.49 18.32 57 18874 61938 110508430
Loose associations 47.96 18.32 9 18922 85 110570283
Loss of consciousness 47.23 18.32 104 18827 196202 110374166
Cogwheel rigidity 46.27 18.32 19 18912 3679 110566689
Peripheral swelling 46.23 18.32 7 18924 404027 110166341
Hallucination, auditory 45.35 18.32 37 18894 26360 110544008
Pneumonia aspiration 44.65 18.32 62 18869 81171 110489197
Confusional state 44.33 18.32 178 18753 468502 110101866
Psychiatric decompensation 44.21 18.32 21 18910 5744 110564624
Diarrhoea 43.22 18.32 81 18850 1139424 109430944
Cerebellar syndrome 42.43 18.32 21 18910 6281 110564087
Polyuria 41.77 18.32 30 18901 17708 110552660
Tardive dyskinesia 41.55 18.32 27 18904 13552 110556816
Restlessness 40.39 18.32 49 18882 56210 110514158
Circulatory collapse 40.30 18.32 43 18888 42950 110527418
Rash 40.13 18.32 49 18882 820915 109749453
Prescribed overdose 39.65 18.32 61 18870 87520 110482848
Renal hypertension 38.59 18.32 9 18922 258 110570110
Hypersensitivity 38.02 18.32 11 18920 403987 110166381
Mydriasis 37.94 18.32 31 18900 22126 110548242
Completed suicide 37.89 18.32 109 18822 242272 110328096
Arthropathy 37.88 18.32 3 18928 287519 110282849
Compartment syndrome 37.74 18.32 19 18912 5891 110564477
Hyposmia 37.51 18.32 12 18919 1139 110569229
Sinus tachycardia 37.36 18.32 42 18889 44451 110525917
Abulia 35.96 18.32 12 18919 1301 110569067
Pressure of speech 35.79 18.32 12 18919 1320 110569048
Urinary retention 35.07 18.32 51 18880 69632 110500736
Drug hypersensitivity 34.99 18.32 17 18914 454073 110116295
Intentional product misuse 34.93 18.32 73 18858 132831 110437537
Leukopenia 34.84 18.32 78 18853 148713 110421655
Hypotension 34.61 18.32 179 18752 523670 110046698
Cardio-respiratory arrest 34.46 18.32 67 18864 115769 110454599
Hyperhidrosis 34.01 18.32 89 18842 187209 110383159
Hyperprolactinaemia 33.03 18.32 18 18913 6557 110563811
Resting tremor 32.77 18.32 12 18919 1711 110568657
Brachial plexus injury 32.52 18.32 7 18924 138 110570230
Stomatitis 32.52 18.32 4 18927 270238 110300130
Alopecia 32.41 18.32 11 18920 364742 110205626
Swelling 32.23 18.32 10 18921 351031 110219337
Pain in extremity 32.17 18.32 22 18909 487096 110083272
Hyperchloraemia 32.08 18.32 11 18920 1295 110569073
Miosis 31.97 18.32 28 18903 21955 110548413
Pneumonia 31.73 18.32 64 18867 876650 109693718
Obsessive-compulsive symptom 31.71 18.32 8 18923 321 110570047
Mental disorder 31.52 18.32 36 18895 38755 110531613
Feelings of worthlessness 31.51 18.32 9 18922 581 110569787
Headache 31.44 18.32 65 18866 882312 109688056
Patient elopement 31.17 18.32 8 18923 344 110570024
Catatonia 31.02 18.32 21 18910 11279 110559089
Dermatitis bullous 31.01 18.32 25 18906 17504 110552864
Bronchial hyperreactivity 30.56 18.32 14 18917 3530 110566838
Apathy 30.53 18.32 24 18907 16215 110554153
Withdrawal syndrome 30.50 18.32 32 18899 31348 110539020
Seizure 30.34 18.32 95 18836 221090 110349278
Livedo reticularis 30.26 18.32 16 18915 5490 110564878
Hepatic cytolysis 30.22 18.32 42 18889 55011 110515357
Systemic lupus erythematosus 30.03 18.32 4 18927 254334 110316034
Psychiatric symptom 29.87 18.32 19 18912 9194 110561174
Blood prolactin increased 29.87 18.32 15 18916 4627 110565741
Product dose omission issue 29.84 18.32 9 18922 321773 110248595
Therapeutic product effect incomplete 29.67 18.32 95 18836 223710 110346658
Otorrhoea 29.67 18.32 12 18919 2236 110568132
Urticaria 29.42 18.32 9 18922 318848 110251520
Aggression 29.31 18.32 43 18888 59167 110511201
Ventricular dyskinesia 29.07 18.32 8 18923 451 110569917
Tension 28.60 18.32 15 18916 5063 110565305
Speech disorder 28.03 18.32 43 18888 61526 110508842
Abdominal pain 27.91 18.32 28 18903 512961 110057407
Illusion 27.48 18.32 11 18920 1996 110568372
Social anxiety disorder 27.14 18.32 9 18922 957 110569411
Retroplacental haematoma 27.12 18.32 6 18925 135 110570233
Hyponatraemia 26.71 18.32 90 18841 217563 110352805
Post-anoxic myoclonus 26.48 18.32 5 18926 49 110570319
Hypertonia 26.42 18.32 17 18914 8389 110561979
Breast disorder 25.96 18.32 11 18920 2303 110568065
Abdominal discomfort 25.72 18.32 18 18913 393840 110176528
Adverse drug reaction 25.45 18.32 56 18875 105503 110464865
Cor pulmonale acute 25.08 18.32 8 18923 752 110569616
Rheumatoid arthritis 24.99 18.32 10 18921 299603 110270765
Synovitis 24.81 18.32 8 18923 274084 110296284
Contraindicated product administered 24.79 18.32 6 18925 248261 110322107
Generalised tonic-clonic seizure 24.62 18.32 38 18893 54642 110515726
Asphyxia 24.57 18.32 20 18911 14195 110556173
Heat stroke 24.41 18.32 10 18921 1925 110568443
Infection 24.39 18.32 16 18915 362184 110208184
Intellectual disability 24.19 18.32 10 18921 1969 110568399
Drug level increased 24.11 18.32 35 18896 47684 110522684
Hypothermia 24.11 18.32 26 18905 26276 110544092
Lower respiratory tract infection 24.03 18.32 6 18925 243100 110327268
Auditory disorder 23.73 18.32 9 18922 1415 110568953
Dermo-hypodermitis 23.34 18.32 9 18922 1479 110568889
Abnormal behaviour 23.27 18.32 31 18900 39008 110531360
Anhedonia 23.14 18.32 20 18911 15408 110554960
Cough 23.10 18.32 27 18904 461614 110108754
Adrenergic syndrome 23.09 18.32 6 18925 271 110570097
Orthostatic hypotension 23.06 18.32 41 18890 66208 110504160
Dialysis 22.72 18.32 22 18909 19597 110550771
Nausea 22.60 18.32 122 18809 1235568 109334800
Dyspraxia 22.42 18.32 6 18925 304 110570064
Glomerular filtration rate abnormal 22.40 18.32 10 18921 2373 110567995
Hypoaesthesia 22.37 18.32 13 18918 314210 110256158
Onychophagia 22.33 18.32 5 18926 119 110570249
Paralogism 21.91 18.32 4 18927 32 110570336
Status epilepticus 21.85 18.32 27 18904 31544 110538824
Blister 21.73 18.32 6 18925 227370 110342998
Psychomotor skills impaired 21.51 18.32 14 18917 7044 110563324
Sepsis 21.31 18.32 15 18916 327331 110243037
Disorientation 21.16 18.32 41 18890 70630 110499738
Clonus 21.12 18.32 15 18916 8701 110561667
Wound 20.94 18.32 7 18924 234430 110335938
Contusion 20.79 18.32 7 18924 233354 110337014
Obesity 20.71 18.32 54 18877 113297 110457071
Drug screen false positive 20.48 18.32 8 18923 1361 110569007
Sedation 20.35 18.32 40 18891 69643 110500725
Gastrointestinal disorder 20.29 18.32 8 18923 241944 110328424
Self-destructive behaviour 20.22 18.32 7 18924 848 110569520
Discomfort 19.90 18.32 6 18925 214701 110355667
Lactic acidosis 19.89 18.32 47 18884 92764 110477604
Negative symptoms in schizophrenia 19.48 18.32 5 18926 215 110570153
Incoherent 19.37 18.32 14 18917 8344 110562024
Gastroduodenal ulcer 19.35 18.32 7 18924 964 110569404
Potentiating drug interaction 19.33 18.32 16 18915 11627 110558741
Muscle spasms 19.11 18.32 12 18919 278145 110292223
Blood creatine phosphokinase increased 19.03 18.32 40 18891 73037 110497331
Long QT syndrome 19.00 18.32 13 18918 7105 110563263
Pleurothotonus 18.85 18.32 9 18922 2489 110567879
Flat affect 18.83 18.32 9 18922 2496 110567872
Intestinal obstruction 18.60 18.32 33 18898 53194 110517174
Respiratory depression 18.44 18.32 25 18906 31976 110538392
Bipolar disorder 18.43 18.32 14 18917 8993 110561375
Otitis media 18.42 18.32 13 18918 7463 110562905

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AA04 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:48278 serotonergic drug
CHEBI has role CHEBI:48279 serotonergic antagonist
CHEBI has role CHEBI:149553 anticoronaviral agent
MeSH PA D000928 Antidepressive Agents
MeSH PA D000929 Antidepressive Agents, Tricyclic
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D017367 Selective Serotonin Reuptake Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D049990 Membrane Transport Modulators
FDA EPC N0000175752 Tricyclic Antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:50949 serotonin uptake inhibitor
CHEBI has role CHEBI:77402 EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor

Related Drugs by ATC class:

N06AA Non-selective monoamine reuptake inhibitors 20 drugs
amineptineamitriptylineamoxapinebutriptylinedesipraminedibenzepindimetacrinedosulepindoxepinimipramineimipramine oxideiprindole show all 20 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Obsessive-compulsive disorder indication 191736004 DOID:10933
Depressive disorder off-label use 35489007
Cataplexy off-label use 46263000
Anxiety off-label use 48694002
Panic disorder off-label use 371631005 DOID:594
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Glaucoma contraindication 23986001 DOID:1686
Hyperthyroidism contraindication 34486009 DOID:7998
Acute nephropathy contraindication 58574008
Epilepsy contraindication 84757009 DOID:1826
Bipolar affective disorder, current episode manic contraindication 191618007
Disease of liver contraindication 235856003 DOID:409
Retention of urine contraindication 267064002
Pheochromocytoma contraindication 302835009
Malignant hyperthermia contraindication 405501007
Myocardial infarction in recovery phase contraindication 418044006
Neuroblastoma contraindication 432328008 DOID:769
Atrioventricular Conduction Defect contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Separation anxiety Indication

🐶 Veterinary products

ProductApplicantIngredients
Clomicalm Tablets Virbac AH Inc. 1
Clomipramine Hydrochloride Tablets Mizner Bioscience LLC 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.04 Basic
pKa2 6.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 9.70 PDSP CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Kd 7.42 WOMBAT-PK IUPHAR
Alpha-2A adrenergic receptor GPCR Ki 6.28 PDSP
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.24 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 7.45 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 6.82 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.19 PDSP
5-hydroxytryptamine receptor 6 GPCR Ki 6.95 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 8.50 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.34 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.41 PDSP
Histamine H1 receptor GPCR Ki 8.01 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.70 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 7.66 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.07 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 7.44 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.89 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 7.42 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 6.32 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 6.69 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter IC50 5.56 CHEMBL
Cytochrome P450 2D6 Enzyme Ki 5.66 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 7.40 DRUG MATRIX
Glutathione S-transferase P Enzyme WOMBAT-PK
Voltage-dependent N-type calcium channel subunit alpha-1B Ion channel IC50 5.05 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.71 CHEMBL
D(1A) dopamine receptor GPCR Ki 6.66 PDSP
D(2) dopamine receptor GPCR Ki 6.95 PDSP
Trypanothione reductase Enzyme Ki 5.19 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 7.14 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.94 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 10.40 CHEMBL
D(2) dopamine receptor GPCR Ki 7.25 CHEMBL
Sodium-dependent noradrenaline transporter Transporter IC50 6.05 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 7.15 CHEMBL
Histamine H1 receptor GPCR IC50 9.70 CHEMBL
Serotonin (5-HT) receptor GPCR IC50 8.30 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 5.30 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.29 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 8.08 CHEMBL
Trypanothione reductase Enzyme IC50 5.47 CHEMBL
G protein-activated inward rectifier potassium channel 2 Ion channel BLOCKER IC50 4.40 IUPHAR

External reference:

IDSource
4019687 VUID
N0000147779 NUI
D00811 KEGG_DRUG
17321-77-6 SECONDARY_CAS_RN
2597 RXNORM
C0009010 UMLSCUI
CHEBI:47780 CHEBI
CXX PDB_CHEM_ID
CHEMBL415 ChEMBL_ID
DB01242 DRUGBANK_ID
CHEMBL1200710 ChEMBL_ID
D002997 MESH_DESCRIPTOR_UI
2801 PUBCHEM_CID
2398 IUPHAR_LIGAND_ID
2238 INN_ID
NUV44L116D UNII
373 MMSL
4476 MMSL
d00876 MMSL
003456 NDDF
004614 NDDF
372903001 SNOMEDCT_US
387027004 SNOMEDCT_US
96209002 SNOMEDCT_US
4019492 VANDF
4019687 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8806 CAPSULE 25 mg ORAL NDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8807 CAPSULE 50 mg ORAL NDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8808 CAPSULE 75 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9906 CAPSULE 25 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9907 CAPSULE 50 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9908 CAPSULE 75 mg ORAL NDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7038 CAPSULE 25 mg ORAL ANDA 26 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7039 CAPSULE 50 mg ORAL ANDA 26 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-698 CAPSULE 25 mg ORAL ANDA 27 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-699 CAPSULE 50 mg ORAL ANDA 27 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-700 CAPSULE 75 mg ORAL ANDA 27 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-683 CAPSULE 25 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-684 CAPSULE 50 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-685 CAPSULE 75 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-849 CAPSULE 25 mg ORAL ANDA 21 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-850 CAPSULE 50 mg ORAL ANDA 21 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-851 CAPSULE 75 mg ORAL ANDA 21 sections
Clomipramine hydrochloride Human Prescription Drug Label 1 27241-210 CAPSULE 25 mg ORAL ANDA 23 sections
Clomipramine hydrochloride Human Prescription Drug Label 1 27241-211 CAPSULE 50 mg ORAL ANDA 23 sections
Clomipramine hydrochloride Human Prescription Drug Label 1 27241-212 CAPSULE 75 mg ORAL ANDA 23 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42571-342 CAPSULE 25 mg ORAL ANDA 23 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42571-343 CAPSULE 50 mg ORAL ANDA 23 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42571-344 CAPSULE 75 mg ORAL ANDA 23 sections
CLOMIPRAMINE HYDROCHLORIDE Human Prescription Drug Label 1 46708-407 CAPSULE 25 mg ORAL ANDA 22 sections
CLOMIPRAMINE HYDROCHLORIDE Human Prescription Drug Label 1 46708-408 CAPSULE 50 mg ORAL ANDA 22 sections
CLOMIPRAMINE HYDROCHLORIDE Human Prescription Drug Label 1 46708-409 CAPSULE 75 mg ORAL ANDA 22 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51407-757 CAPSULE 25 mg ORAL ANDA 26 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51407-758 CAPSULE 50 mg ORAL ANDA 26 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51407-759 CAPSULE 75 mg ORAL ANDA 26 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51672-4011 CAPSULE 25 mg ORAL ANDA 26 sections